Novel LMNA mutations in patients with Emery-Dreifuss muscular dystrophy and functional characterization of four LMNA mutations

Juergen Scharner, Charlotte A Brown, Matthew Bower, Susan T Iannaccone, Ismail A Khatri, Diana Escolar, Erynn Gordon, Kevin Felice, Carol A Crowe, Carla Grosmann, et al.

► To cite this version:

Juergen Scharner, Charlotte A Brown, Matthew Bower, Susan T Iannaccone, Ismail A Khatri, et al.. Novel LMNA mutations in patients with Emery-Dreifuss muscular dystrophy and functional characterization of four LMNA mutations. Human Mutation, 2011, 32 (2), pp.152. 10.1002/humu.21361 . hal-00610794

HAL Id: hal-00610794

<https://hal.science/hal-00610794>

Submitted on 25 Jul 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Novel *LMNA* mutations in patients with Emery-Dreifuss muscular dystrophy and functional characterization of four *LMNA* mutations

Journal:	<i>Human Mutation</i>
Manuscript ID:	humu-2010-0292.R1
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	14-Aug-2010
Complete List of Authors:	<p>Scharner, Juergen; King's College London, Randall Division of Cell and Molecular Biophysics</p> <p>Brown, Charlotte; BD Diagnostics</p> <p>Bower, Matthew; Fairview-University Medical Center, Department of Pediatrics</p> <p>Iannaccone, Susan; UT Southwestern Medical Center, Texas</p> <p>Scottish Rite Hospital for Children</p> <p>Khatri, Ismail; Shifa International Hospital, Division of Neurology</p> <p>Escolar, Diana; Children's National Medical Center, Research Center for Genetic Medicine</p> <p>Gordon, Erynn; Coriell Institute for Medical Research</p> <p>Felice, Kevin; Hospital for Special Care, Department of Neuromuscular Medicine</p> <p>Crowe, Carol; MetroHealth Medical Center, Department of Pediatrics</p> <p>Grosman, Carla; Rady Children's Hospital San Diego, Department of Neurology</p> <p>Meriggioli, Matthew; University of Illinois, Department of Neurology and Rehabilitation</p> <p>Asamoah, Alexander; Weisskopf Child Evaluation Center, University of Louisville, Department of Pediatrics</p> <p>Gordon, Ora; Cedar-Sinai Medical Center, Medical Genetics Institute</p> <p>Gnocchi, Viola; King's College London, Randall Division of Cell and Molecular Biophysics</p> <p>Ellis, Juliet; King's College London, Randall Division of Cell and Molecular Biophysics</p> <p>Mendell, Jerry; Ohio State University, and the Research Institute at Nationwide Children's Hospital, Departments of Pediatrics and Neurology</p> <p>Zammit, Peter; King's College London, Randall Division of Cell and Molecular Biophysics</p>
Key Words:	lamin A, lamin B, emerin, EDMD, LGMD, L-CMD, nuclear envelope, nuclear lamina, laminopathy, skeletal muscle

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SCHOLARONE™
Manuscripts

For Peer Review

Novel *LMNA* mutations in patients with Emery-Dreifuss muscular dystrophy and functional characterization of four *LMNA* mutations

Juergen Scharner,^{1,15} Charlotte A. Brown,^{2,15} Matthew Bower,³ Susan T. Iannaccone,⁴ Ismail A. Khatri,⁵ Diana Escolar,⁶ Erynn Gordon,⁷ Kevin Felice,⁸ Carol A. Crowe,⁹ Carla Grosmann,¹⁰ Matthew N. Meriggioli,¹¹ Alexander Asamoah,¹² Ora Gordon,¹³ Viola F. Gnocchi,¹ Juliet A. Ellis,¹ Jerry R. Mendell,^{14*} Peter S. Zammit^{1*}

¹Randall Division of Cell and Molecular Biophysics, King's College London, UK;

²BD Diagnostics, Durham, NC, USA;

³Department of Pediatrics, Fairview-University Medical Center, Minneapolis, MN;

⁴Texas Scottish Rite Hospital for Children, UT Southwestern Medical Center, Dallas, TX;

⁵Division of Neurology, Shifa International Hospital, Islamabad, Pakistan;

⁶Research Center for Genetic Medicine, Children's National Medical Center, Washington, D.C.;

⁷Coriell Institute for Medical Research, Camden, NJ

⁸Department of Neuromuscular Medicine, Hospital for Special Care, New Britain, CT;

⁹Department of Pediatrics, MetroHealth Medical Center, Cleveland, OH;

¹⁰Department of Neurology, Rady Children's Hospital San Diego, San Diego, CA;

¹¹Department of Neurology and Rehabilitation, University of Illinois, Chicago, IL;

¹²Department of Pediatrics, Weisskopf Child Evaluation Center, University of Louisville, KY;

¹³Medical Genetics Institute, Cedar-Sinai Medical Center, Los Angeles, CA;

¹⁴Department of Pediatrics and Neurology, Ohio State University, and the Research Institute at Nationwide Children's Hospital, Columbus, OH;

¹⁵These authors contributed equally to this work

* These authors are joint last authors.

Correspondence to: peter.zammit@kcl.ac.uk; jerry.mendell@nationwidechildrens.org

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Mutations in *LMNA* cause a variety of diseases affecting striated muscle including autosomal-Emery-Dreifuss muscular dystrophy (EDMD), *LMNA*-associated congenital muscular dystrophy (L-CMD) and limb-girdle muscular dystrophy type 1B (**LGMD1B**). Here, we describe novel and recurrent *LMNA* mutations identified in 50 patients from the USA and Canada, which is the first report of the distribution of *LMNA* mutations from a large cohort outside Europe. This augments the number of *LMNA* mutations known to cause EDMD by 16.5%, equating to an increase of 5.9% in the total known *LMNA* mutations. Eight patients presented with p.R249W/Q or p.E358K mutations and an early onset EDMD phenotype: two mutations recently associated with L-CMD. Importantly, 15 mutations are novel and include eight missense mutations (p.R189P, p.F206L, p.S268P, p.S295P, p.E361K, p.G449D, p.L454P and p.W467R), three splice site mutations (c.IVS4+1G>A, c.IVS6-2A>G, c.IVS8+1G>A), one duplication/in frame insertion (p.R190dup), one deletion (p.Q355del) and two silent mutations (p.R119R and p.K270K). Analysis of 4 of our lamin A mutations showed that some caused nuclear deformations and lamin B re-distribution in a mutation specific manner. Together, this study significantly augments the number of EDMD patients on the database and describes 15 novel mutations that underlie EDMD, which will contribute to establishing genotype-phenotype correlations.

Keywords: lamin A, lamin B, emerin, EDMD, LGMD, L-CMD, nuclear envelope, nuclear lamina, laminopathy, skeletal muscle

Introduction

Emery-Dreifuss muscular dystrophy (EDMD) manifests in childhood with slowly progressive muscle weakness with a scapulo-humeroperoneal distribution, associated with contractures of the Achilles tendon, neck and elbow. Cardiac involvement is a consistent feature associated with nearly all patients by the third decade, initially involving arrhythmias, progressing towards complete heart block with a substantial risk of sudden death in middle age (Emery, 1989).

Both X-linked and autosomal forms of EDMD have been described. Mutations in the *EMD* gene (Xq28, MIM# 300384) have been identified in patients with X-linked EDMD (X-EDMD, MIM# 310300) (Bione, et al., 1994). *EMD* encodes emerin, a small integral membrane protein located at the inner nuclear membrane and a member of the LEM domain proteins (Wagner and Krohne, 2007). Mutations in the *LMNA* gene (1q21.3, MIM# 150330), encoding the A-type lamins - lamin A and C by alternative splicing (Figure 1A), have been found in patients with autosomal dominant (EDMD2, MIM# 181350) (Bonne, et al., 1999) and autosomal recessive (EDMD3, MIM# 604929) (Raffaele Di Barletta, et al., 2000) forms of EDMD. *LMNA* mutations are also associated with a congenital muscular dystrophy termed *LMNA*-related congenital muscular dystrophy (L-CMD, MIM# 613205) (Quijano-Roy, et al., 2008). Lamins A and C are type V intermediate filament proteins, and together with B-type lamins, are major components of the nuclear lamina: a proteinaceous meshwork underlying the inner nuclear membrane thought to provide a structural framework for the nuclear envelope and an anchoring site at the nuclear periphery for interphase chromosomes. Recently, it has been shown that mutations in the *FHL1* gene (Xq27.2, MIM# 300163) are also associated with EDMD (Gueneau, et al., 2009). *FHL1* encodes a LIM domain protein

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

containing 2 zinc fingers in tandem, which has been implicated in sarcomere assembly (Gueneau, et al., 2009; McGrath, et al., 2006).

Emerin and lamin A/C are thought to have a close functional relationship, even though the phenotypes caused by *EMD* and *LMNA* mutations are clinically different (Bonne, et al., 2003; Meune, et al., 2006). In fact, direct interaction between emerin and lamin A has been demonstrated by multiple experimental techniques (Clements, et al., 2000; Lee, et al., 2001) and emerin localization has been shown to be affected by mutant lamin A (Holt, et al., 2003). *LMNA* mutations have also been detected in patients with autosomal dominant limb-girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B, MIM# 159001) (Muchir, et al., 2000). While the clinical phenotype of LGMD1B overlaps with EDMD, there are differences, for example, LGMD1B is characterized by slowly progressive pelvic girdle weakness, with a sparing of the lower leg muscles. In addition, contractures and cardiac disturbances tend to occur later in life in LGMD1B, compared to EDMD patients (Muchir, et al., 2000).

In addition to EDMD, LGMD1B, L-CMD and isolated dilated cardiomyopathy and conduction-system disease (CMD1A, MIM# 115200) (Fatkin, et al., 1999) that primarily affect striated muscle, ‘laminopathies’ also affect other tissues. Such laminopathies include Dunningan-type familial partial lipodystrophy (FPLD, MIM# 151660) (Hegele, et al., 2000; Shackleton, et al., 2000; Speckman, et al., 2000), autosomal recessive Charcot-Marie-Tooth Disorder Type 2B1 (CMT2B1, MIM# 605588) (De Sandre-Giovannoli, et al., 2002), mandibuloacral dysplasia (MAD, MIM# 248370) (Novelli, et al., 2002; Shen, et al., 2003), **Hutchinson-Gilford progeria syndrome (HGPS, MIM# 176670)** (De Sandre-Giovannoli, et al., 2003; Eriksson, et al., 2003), and autosomal dominant atypical Werner’s syndrome

(WRN, MIM# 150330) (Chen, et al., 2003). In addition, both intra-familial and inter-familial variability of phenotypes associated with *LMNA* mutations is a common feature (Shen, et al., 2003; Simha, et al., 2003; Speckman, et al., 2000; Vytöpil, et al., 2002).

A clear genotype-phenotype correlation has not been identified for most laminopathies, although HGPS tends to correlate with C-terminal splicing defects, while other conditions (i.e. MAD, WRN and CMT2B1) result from 'hot spot' missense mutations. For other laminopathies including EDMD, the pathogenic *LMNA* mutations are distributed throughout the gene (Scharner, et al., 2010). The *LMNA* gene contains 12 exons and encodes both lamin A and C by alternative splicing, both sharing the first 566 amino acids (Lin and Worman, 1993). In addition to their role in the nuclear lamina, lamins also interact with numerous integral proteins of the inner nuclear membrane and proteins of nuclear pore complexes (Schirmer and Foisner, 2007), orchestrating a number of cellular and molecular processes including nuclear envelope assembly, maintenance of nuclear architecture, DNA synthesis, chromatin organization, gene transcription, cell cycle progression, cell differentiation and migration and response to DNA damage (Broers, et al., 2006; Prokocimer, et al., 2009; Verstraeten, et al., 2007), processes that could be differentially affected by specific mutations.

This report describes novel and recurrent *LMNA* mutations identified in 50 patients referred for clinical testing for a suspected diagnosis of EDMD or LGMD in the USA and Canada. This is also the first report of the distribution of *LMNA* mutations from a large patient cohort from outside Europe, and augments the EDMD mutation database by ~6%. Importantly, amongst these were 15 novel pathogenic *LMNA* mutations that include eight missense mutations (p.R189P, p.F206L, p.S268P, p.S295P, p.E361K, p.G449D, p.L454P and

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

p.W467R), three splice site mutations (c.IVS4+1G>A, c.IVS6-2A>G, c.IVS8+1G>A), one duplication/in frame insertion (p.R190dup), one deletion (p.Q355del) and two silent mutations (p.R119R and p.K270K). Examining 4 *LMNA* of our mutations further, we found that mutations located in various protein domains differentially affect basic nuclear characteristics including nuclear size, shape and protein distribution. Taken together, we provide clinical and *in vitro* data to confirm the complex pathogenicity associated with *LMNA* mutations, suggesting that genetic background is also a major player in the severity of the expressed phenotype of autosomal EDMD.

For Peer Review

Material and Methods

Patients

The 255 patients reported in this manuscript were referred to either the DNA Diagnostic Laboratory at Carolinas Medical Center (1996-2001) or the Molecular Diagnostics Laboratory at the University of Minnesota (2001-2003) from the United States of America and Canada for mutation analysis of the *LMNA* gene (GenBank Accession Number RefSeq NM_170707.2). The clinical diagnoses of patients referred for testing included muscular dystrophies of the EDMD, LGMD, congenital, Becker (BMD) and fascioscapulohumeral (FSHD) types, as well as spinal muscular atrophy (SMA). This study was approved by the Institutional Review Board at both Carolinas Medical Center and the University of Minnesota.

DNA Isolation and Polymerase Chain Reaction

DNA extracted from peripheral blood by either standard proteinase K/phenol-chloroform extraction procedures on a 341 Nucleic Acid Extractor (Perkin-Elmer, Norwalk, CT) or using a QIamp DNA Blood Mini Kit (Qiagen, Valencia, CA). Exons 1-12 of *LMNA* were amplified by PCR as previously described (Brown et al. 2001). Primers used for the PCR reaction are listed in table 1.

Sequencing

Amplimers were extracted from agarose gel using a Gel Extraction Kit (Qiagen, Valencia, CA) and each exon sequenced directly from both strands using the Prism Ready Reaction DyeDeoxy Terminator Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) with analysis of sequenced products on either an ABI377 or ABI3100 Genetic Analyzer.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Generated sequences were compared to the published *EMD* or *LMNA* gene sequence using the Sequence Navigator (Applied Biosystems, Foster City, CA) or Sequencher (Gene Codes Corporation, Ann Arbor, MI) software packages. Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.

Retroviral expression vectors

The retroviral (RV) backbone *pMSCV-puro* (Clontech, Mountain View, CA) was modified to replace the puromycin selection gene with *eGFP*, to create *pMSCV-IRES-eGFP*, which served as the RV control vector (Zammit, et al., 2006). Wild type (Motsch, et al., 2005) and four mutant human lamin A pEGFP-C1 cDNAs (R25P, R249W, N456I and R541P) were sub-cloned into pMSCV-IRES-eGFP to generate control *pMSCV-laminA-IRES-eGFP* and *pMSCV-laminA-R25P-IRES-eGFP*, *pMSCV-laminA-R249W-IRES-eGFP*, *pMSCV-laminA-N456I-IRES-eGFP* and *pMSCV-laminA-R541P-IRES-eGFP*, producing either wildtype lamin A as a control, or mutant lamin A species, as a bicistronic message with eGFP (Figure 2C). Retroviral constructs, together with an ecotropic packaging plasmid, were transiently co-transfected into 293T cells to produce non-replicating retrovirus and the supernatant harvested 48, 60 and 72 hours later.

Cell Culture and Retroviral infection

C2C12 mouse myoblast cells were grown and maintained in DMEM-Glutamax (Invitrogen, Paisley, UK) supplemented with 10% FBS (PAA, Somerset, UK) and 1% Penicillin/Streptomycin (Sigma, Dorset, UK). A total of 20,000 C2C12 cells were plated into one well of a 6-well plate and exposed to retroviral supernatant (diluted 1:5 in growth

medium supplemented with 4 μ g/mL polybrene) for at least 12 hours, before they were analyzed at least 24 hours later.

Morphometric Analysis

To quantify the morphological abnormalities of nuclei such as elongation or lobulation, we measured the perimeter and the area of at least 120 nuclei from 3 independent experiments and calculated the nuclear roundness or contour ratio ($4\pi \text{ area/circumference}^2$) (Goldman, et al., 2004). The contour ratio of a circle is 1 and the value gets smaller with an increased degree of lobulation. Micrographs of infected C2C12 cells stained for lamin B were analyzed using the NIH ImageJ software (<http://rsbweb.nih.gov/ij/>). To calculate the perimeter and area of the nuclei, they were outlined using the polygon selection tool and measured with ImageJ. A two-tailed Student's t-test was used to calculate the statistical significance of the result.

Immunostaining

Cells were fixed with 4% paraformaldehyde (PFA) for 10 minutes, permeabilized with 0.5% Triton X-100 in PBS for 10 minutes and blocked with 5% normal goat serum and 5% normal swine serum (or 5% horse serum and 5% normal swine serum when primary antibodies raised in goat were used) in PBS/0.025% Tween20 for 1 hour at room temperature. After incubation with primary antibody in 1% serum (goat anti-lamin A C20 1:100, goat anti-lamin A/C N18 1:200, goat anti-lamin B (recognises all forms) M20 1:200 (Santa Cruz Biotechnology, Santa Cruz, CA); rabbit anti-emerin AP8 1:100 (Ellis, et al., 1998); rabbit anti-GFP 1:500 (Molecular Probes, Eugene, OR) and mouse anti-GFP 7.1&13.1 1:100 (Roche, Mannheim, Germany)), the cells were washed and exposed to fluorescently coupled secondary antibodies (Alexa Fluor - Molecular Probes, Eugene, OR) at a concentration of

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1:500 and mounted in DAPI containing mounting medium. F-actin was stained by exposing the PFA-fixed cells to Alexa Fluor 633 conjugated phalloidin (Molecular Probes, Eugene, OR) (diluted 1:50 in PBS+0.025% Tween20) for 30 minutes prior washing and mounting the slides with DAPI containing mounting medium.

Fluorescence intensity measurement

Representative nuclei stained for DAPI, lamin A and lamin B respectively were analyzed using the “Plot Profile” tool in ImageJ. The x, y coordinates were imported in MS Excel to compile the histogram.

Western Blot

Harvested cells were re-suspended in suspension buffer (100mM NaCl, 10mM TrisHCl pH7.5, 1mM EDTA) supplemented with proteinase inhibitors and lysed in loading buffer (Laemmli, 1970). The protein concentration was determined with the Bio-Rad DC Protein Assay based on the Lowry method (Lowry, et al., 1951). Samples were immunoblotted with the following antibodies: goat anti-lamin A/C N18 1:1000 (Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti-GFP 1:2000 (Molecular Probes, Eugene, OR), mouse anti β -tubulin 1:1000 (DSHB, Iowa City, IA), and then probed with HRP-conjugated secondary antibodies (ECL™ sheep anti mouse or rabbit 1:5000, GE Healthcare, Uppsala, Sweden; sheep anti goat SO84 1:5000, Abcam, Cambridge, UK) and developed using ECL from GE Healthcare. Band intensity was quantified using ImageJ.

Results

Clinical and genetic information on 50 patients

This is the first report on the distribution of *LMNA* mutations from a large patient cohort from the USA and Canada. Among the 255 referrals, 23 patients (9.0%) were found to possess *EMD* gene mutations (manuscript in preparation) and 61 individuals (23.9%) were found to have *LMNA* mutations. Clinical and genetic information on 11 of the patients with *LMNA* mutations has been published previously (Brown, et al., 2001). The mutations identified in the remaining 50 patients and their clinical information are presented in Tables 2 and 3.

Amongst the 50 individuals found to carry a *LMNA* mutation, 37 different mutations (in 36 patients) were detected, scattered throughout the gene (Figure 1A and Table 2 and 3). The majority of *LMNA* mutations identified here are missense mutations (27/37; 73.0%), with an additional 2 mutations being small in-frame insertions or deletions (2/37; 5.4%). Seven mutations were found to be deleterious mutations at conserved donor or acceptor splice site sequences (5/37; 13.5%) or silent mutations (2/37; 5.4%). The final mutation in patient 2974 was the only frame shift mutation, presumably encoding both truncated lamin A and lamin C protein species (1/37; 2.7%). This patient had a predominantly cardiac phenotype with only mild skeletal muscle weakness developing at age 50. These results are consistent with the phenotypes of other patients found to possess truncating mutations (Benedetti, et al., 2007). The most common previously reported *LMNA* mutation, c.1357C>T (p.R453W), was also the most frequent in our study group, being found in 6 (12.0%) of the patients. Two mutations were found to be confined to the lamin A protein, p.G602S and p.R644C, suggesting that alterations in the far C-terminus of the lamin A protein alone is sufficient to cause EDMD2.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

A few of the patients with p.R249W and p.E358K and p.N39S presented at <1-2 years old (Table 2), which is below the average onset age for a severe EDMD2 case (32 months). Interestingly, these mutations have recently been reported to be associated with the congenital muscular dystrophy L-CMD, where the age of onset is from birth to 1 year.

Five patients (33, 7975, 1412, 6388 and 2660) had mutations located in non-coding regions at the exon-intron or intron-exon junctions affecting the universally conserved GT and AG di-nucleotides. Therefore, these mutations likely affect pre-mRNA splicing although RNA analysis was not performed. These patients with intronic splice site mutations presented with an EDMD phenotype (Table 2). A further three patients (91, 778 and 2018) had two silent mutations located on either the first or last nucleotides of an exon, which could also modify splicing.

Of the 45 patients for whom a family history was available, there was an approximately even split between cases that appeared to be familial in origin (21/45 [46.7%]) compared to cases that appeared to be sporadic (24/45 [53.3%]). Indeed, for our commonest mutation for which we have information (p.R453W), 2 cases were familial and 3 cases were sporadic. DNA analysis was only performed on the family members of 3 cases classed as sporadic (patients 6537, 3734, and 778), which confirmed the *de novo* origin of mutations in these individuals. It is possible of course, that apparently sporadic cases may have relatives who are currently asymptomatic gene mutation carriers.

Novel pathogenic LMNA mutations

Of these 37 LMNA mutations, 15 are novel pathogenic LMNA mutations (highlighted in red in Figure 1A and B and Table 2 and 3), not previously published or listed in any of the

following databases: The Universal Mutation Database (UMD) (<http://www.umd.be/>), Human Intermediate Filament Database (<http://www.interfil.org/>) (Szeverenyi, et al., 2006) and the Leiden Open Variation Database (LOVD) (<http://www.dmd.nl/>). This augments the number of *LMNA* mutations known to cause EDMD by 16.5%, equating to an increase of 5.9% in the total known *LMNA* mutations. These 15 mutations include eight missense mutations (p.R189P, p.F206L, p.S268P, p.S295P, p.E361K, p.G449D, p.L454P and p.W467R), three splice site mutations (c.IVS4+1G>A, c.IVS6-2A>G, c.IVS8+1G>A), one duplication/in frame insertion (p.R190dup), one deletion (p.Q355del) and two silent mutations (p.R119R and p.K270K). The majority of patients carrying novel mutations (13/15) show symptoms associated with EDMD, while patient 2018 carrying the **silent mutation c.810G>A (p.K270K)**, was initially diagnosed with BMD, prior to screening for *LMNA* mutations. Patient 91 carrying the **silent mutation c.357C>T (p.R119R)** presented with an LGMD1B phenotype with cardiac involvement. Of the 12 mutations located in the coding region of *LMNA*, four are in coil 1B, five are in coil 2 of the central rod domain, and the remaining three are located on conserved residues in the Ig-like fold of the tail of the lamin A/C protein (Figure 1A).

The *LMNA* gene is well conserved with 33% homology of the coding region between *D. melanogaster* and *Homo sapiens*. The majority of our novel missense mutations and one insertion (7/10) affect residues conserved between species from *C. elegans* to *Homo sapiens*, whilst the remaining two missense mutations and one deletion (p.R189P, p.S268P and p.Q355del) are all located in the central rod domain, and affect residues that are less conserved between species (Figure 1B).

Effects of lamin A mutants on myogenic cells

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Having described pathogenic *LMNA* mutations in patients, we next sought to gain insight into the effects of several mutant human lamin A species on myogenic cells. We chose four mutations from this (p.R249W and p.R541P) and our previous study (p.R25P and p.N456I) (Brown, et al., 2001) that span the *LMNA* gene and affect different domains of the protein. The majority of pathogenic lamin A mutations are dominant, with usually only one allele being affected in patients. This suggests that in cases that are not caused by haploinsufficiency, the amount of mutated protein that is necessary to create a phenotype is relatively small. Importantly, patient myoblasts are not readily available and a commonly used DNA delivery method is cell transfection, which results in dramatic over-expression (up to 25 fold) of mutant lamin A (Bechert, et al., 2003).

Retroviral infection is efficient in mouse C2C12 myogenic cells with an infection rate of >98% routinely obtained (data not shown). Retroviral-mediated constitutive expression of wild-type lamin A clearly shows the co-expression of lamin A and eGFP, with cells with higher levels of eGFP generally also expressing higher levels of lamin A (Figure 2A). In addition to efficiently targeting >98% cells, retroviral-mediated constitutive expression also has the advantage that the levels of exogenous proteins are generally only moderately elevated compared to endogenous proteins. Western blot analysis confirmed increased levels of exogenous wild type and mutant lamin A was only on average 1.3-1.7 fold higher than controls (Figure 2B) resembling a more physiological condition. Endogenous expression level of lamin C was not affected (Figure 2B).

The presence of lamin A-R25P and lamin A-R249W results in abnormal nuclear morphology

We observed large differences in nuclear size depending on the lamin variant expressed. While a small increase in the nuclear cross-sectional area was observed in cells treated with the RV control, the average nuclear size was further significantly increased in the presence of lamin A-R25P (29% increase) and lamin A-R249W (34% increase) compared to lamin A-wild type infected cells (Figure 2D). Constitutive expression of lamin A-wild type did not have an effect on nuclear size. The dramatic increase in nuclear size coincides with changes in nuclear morphology. Normal ovoid nuclear morphology was observed when cells were infected with RV control (contour ratio 0.95 ± 0.003) or lamin A-wild-type (0.95 ± 0.002). The presence of either lamin A-R25P or lamin A-R249W however, resulted in abnormal nuclear morphology with simple or multiple lobules of the nuclear envelope. The contour ratio was significantly smaller in cells expressing lamin A-R25P (0.87 ± 0.006) and lamin A-R249W (0.85 ± 0.007), reflecting these nuclear distortions (Figure 2E). Changes in both nuclear size and contour ratio occurred concomitantly. This effect was mutation specific however, since the presence of lamin A-N456I or lamin A-R541P did not alter nuclear size or shape.

Mutant lamin A protein species are mislocalised in the nucleus

Abnormalities in mutant lamin A protein distribution were also observed (Figure 3 and 4A-C). Although all the mutant lamin A proteins were present to some degree at the nuclear periphery, there was frequent disorganisation of the lattice, with evidence of lamin A capping, particularly in lamin A-R25P and lamin A-R249W-expressing nuclei (lamin A mislocalization is shown by arrows in Figure 3). There were also more lamin A-positive nuclear speckles present, with a greater size distribution compared with cells expressing lamin A-wild type. Prominent lamin A speckles distributed throughout the nucleus were particularly evident in many cells expressing the lamin A-N456I and lamin A-R541P mutant proteins, (lamin A-N456I, $25.9\% \pm 4.0\%$; lamin A-R541P, $9.0\% \pm 3.5\%$) than with the other

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

mutants (Figure 4A and C). Lamin A speckles observed in lamin A-N456I infected cells were generally larger in size compared to those observed in lamin A-R541P infected cells (Figure 4A). When the fluorescence intensity of lamin A together with that of DAPI was plotted on a histogram, lamin A-positive foci did not co-stain with the chromatin (Figure 4B). Nuclear lamin A foci were not analyzed in cells infected with RV control because the fixation protocol used to preserve cellular morphology resulted in endogenous mouse lamin A being weakly detected (Figure 3), compared to the robust immunostaining to the human lamin A species encoded by RVs.

Endogenous lamin B mis-localization in the presence of lamin A-R25P and R249W

To investigate whether other endogenous nuclear envelope components were mislocalised in the presence of the mutant lamin A proteins, we analyzed the expression of several components of the nuclear envelope by immunocytochemistry (Figures 3 and 4D-F). Lamin A and C directly bind emerin *in vitro* (Vaughan, et al., 2001) and have been shown to co-localize with mutant lamin A (Ostlund, et al., 2001). We therefore determined if the expression of our constructs had an effect on emerin localization, and if lamin A-N456I in particular, could cause nuclear foci that strongly immunostain for emerin. However, none of the lamin A mutants induced nuclear foci that contained emerin, confirming previous descriptions (Capanni, et al., 2003; Muchir, et al., 2004) (Figure 3). F-actin staining by standard immunofluorescence microscopy appeared normal, except in cells expressing the p.R25P mutation, where fewer stress fibres were observed (Figure 3).

The localization of lamin B however was changed by the expression of two mutant lamins. In nuclei of cells expressing lamin A-R25P and lamin A-R249W, B-type lamins were lost from one or more poles in some cells (Figure. 3, arrowed and Figure 4D), which was particularly

severe with the p.R249W mutant. The DAPI staining pattern implies the nuclei remain intact, but the redistribution of lamin B is suggestive of nuclear membrane herniation. Figure 4D shows a detailed micrograph of lamin B stained cells infected with either lamin A-wild type, lamin A-R25P or lamin A-R249W. Fluorescent intensity profiles of DAPI and B-type lamin staining across a central axis of the nuclei were calculated (Figure 4E). Whereas the signal for lamin B in cells expressing lamin A-wild type (shown by the histogram) remained constant across the nucleus, in the presence of lamin A-R249W, where the central axis bisects one of the poles, the fluorescence intensity gradually reduced to background levels as the pole was approached. Nuclei of cells infected with lamin A-R25P showed an intermediate phenotype between lamin A-wild type and lamin A-R249W. While less than 10% of nuclei infected with lamin A-wild type, lamin A-N456I and lamin A-R541P were affected, the number of nuclei with a polar loss of lamin B was significantly higher in presence of lamin A-R25P ($19.6\% \pm 2.7\%$) and especially lamin A-R249W ($32.7\% \pm 3.3\%$), with cells containing the R249W mutation being the most severely affected (Figure 4F).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

In this study we report 16 patients with novel, and 34 patients with recurring *LMNA* mutations, increasing the known *LMNA* mutation database by ~5.9% (The Universal Mutation Database (UMD)). Since laminopathies are rare diseases, this significant increase in patient data will hopefully aid genotype/phenotype correlations.

Variable expressivity of the EDMD phenotype is noted in many families illustrating the importance of the genetic background for clinical presentation. One example of highly variable expressivity in EDMD2 is demonstrated by the family of patient 7309, found to be heterozygous for the common p.R453W lamin A/C mutation. The proband was initially diagnosed with a mild form of LGMD1B at age 6, and at age 26, he had mild proximal muscle weakness, contractures and cardiac involvement. The probands father died of heart failure at age 61, at which time he had neck and elbow contractures, but minimal, if any, muscle weakness. The proband’s paternal grandmother was not considered to be affected with EDMD until an autopsy performed at age 88 revealed a skeletal muscle myopathy consistent with this disorder, but a cardiac muscle biopsy exhibited no significant pathology. Another example of the phenomenon of variable expressivity is demonstrated by patient 33, who was found to be heterozygous for an intron 4 splice junction mutation. Whilst both patient 33 and his sister were known to be affected with EDMD2 upon referral for genetic testing, neither of their parents showed any clinical signs of this disorder. Molecular testing indicated that their father carried the splice junction mutation and shortly after receiving this information, presented with cardiac arrhythmia.

Two patients were found to have a missense mutation within codon 541. Patient 198, with a predicted p.R541P mutation within lamin A/C was diagnosed with LGMD1B. She has two affected children, a daughter diagnosed with mild LGMD1B and a son with a severe form of EDMD. A p.R541S mutation was detected in patient 2743 who required a heart transplant at age 13 due to severe DCM. Other members of this family possessing the p.R541S mutation were diagnosed with either dilated cardiomyopathy or LGMD1B, while female mutation carriers had an unusual habitus due to loss of adipose tissue.

We previously reported patient 1325 who is heterozygous for both p.E358K and p.R624H mutations (Brown, et al., 2001). We hypothesized that the compound heterozygous mutations found in this patient may account for her particularly severe phenotype, with the lamin A-specific mutation being either recessive or dominant with incomplete penetrance, as it was detected in her clinically unaffected father. Of note, three other patients in this study were found to be heterozygous for just the p.E358K mutation, and all appear to be severely affected with EDMD, making the role of the second, lamin A-specific mutation, in patient 1325 unclear. In this study, 2 compound heterozygous patients were found, both presenting with an early onset phenotype (marked by # in table 2). Patient 6388, with a severe form of EDMD, was compound heterozygous for c.IVS-1G>T and p.D461Y, two mutations that have been described before in a patient with early onset EDMD (Bakay, et al., 2006). A second severely affected patient (patient 3) was also found to be a compound heterozygote carrying p.R249W and p.R644C mutations. Interestingly, our study population included patients carrying each of these sequence alterations individually, with patient 8281 being heterozygous for the p.R249W alteration and patient 51 being heterozygous for the lamin A-specific p.R644C mutation. As the two latter patients with single mutations are affected with early age-of-onset disease, both of these mutations appear to act in a dominant fashion. This

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

paradox suggests further studies are required to determine the true reason behind modifying effects, if any, of compound heterozygosity on clinical phenotype.

In 2008, Quijano-Roy et al. reported a new form of congenital muscular dystrophy associated with eleven different mutations in the *LMNA* gene (Quijano-Roy, et al., 2008). Notably, affected patients presented with muscle weakness between birth and the first year of life (rather than at an average age of 32 months as seen for EDMD2). L-CMD patients additionally display a dropped head, also not observed in EDMD2. The muscle weakness in L-CMD expresses as selective axial weakness and wasting of the cervicoaxial muscles with a predominantly proximal upper and distal lower limb involvement. Of 50 patients reported in our study, 14 (marked by ¶ in table 2) associated with 11 different singular mutations originating from familial and sporadic origin, expressed a severe EDMD-like phenotype characterised by an onset of <3 years of age or early cardiac involvement. Three mutations (p.N39S, p.R249W and p.E358K) with an early onset were also reported to cause L-CMD (Quijano-Roy, et al., 2008). Three further mutations described here (c.IVS4+1G>A, p.G449D and p.W467R) causing early onset EDMD are novel. The remaining five mutations (p.R249Q, p.S303P, p.R527P, p.T528R and p.R644C) have been previously described as causing EDMD (Benedetti, et al., 2007; Bonne, et al., 1999; Bonne, et al., 2000; Boriani, et al., 2003; Brown, et al., 2001; Fokkema, et al., 2005; Muchir, et al., 2004; Onishi, et al., 2002; Raffaele Di Barletta, et al., 2000; van der Kooi, et al., 2002; Vytöpil, et al., 2003) with R644C causing a large variety of phenotypes including EDMD (Brown, et al., 2001; Csoka, et al., 2004; Mercuri, et al., 2005; Rankin, et al., 2008). We conclude that additional mechanisms must contribute to the disease severity at presentation such as modifier genes or digenism. Patients with mutations in both *EMD* and *LMNA* genes present with a more severe

phenotype (Ben Yaou, et al., 2007), but all our patients were also screened for *EMD* mutations and found to be negative.

Taking the entire lamin A protein, approximately 50% of all pathogenic mutations affect residues that are conserved from man to *C. elegans*. Although mutations in the conserved residues are more likely to cause a phenotype, to date no clear genotype-phenotype correlation has been established. Six of eight novel amino acid substitutions described in this report affect highly conserved residues of the lamin A protein. Two affected residues reported to be pathogenic (p.R189 and p.S268) are located in the central rod domain of lamin A and are not conserved in evolution. Interestingly, both non-conserved residues are mutated to a proline and located adjacent to pathogenic residues. These are p.R190, associated with DCM when mutated to Trp or Gln (Perrot, et al., 2009; Sylvius, et al., 2005), and p.Y267, associated with EDMD and DCM when mutated to His or Cys (Carboni, et al., 2008; Vytopil, et al., 2003). Proline is not found in the centre of a straight alpha-helix, due to its helix breaking attributes (Richardson and Richardson, 1988). Interestingly, 9/30 (30%) of all pathogenic, non-conserved residues in the central rod domain, are substituted to a proline. Eight of these cause either EDMD or DCM while one (p.A57P) has been reported to cause WRN (Chen, et al., 2003). Our data therefore confirms the assumption that the introduction of a proline is more likely to be pathogenic irrespective of amino acid conservation.

Eight patients were found to have mutations located on the exon-intron or intron-exon junctions, suggesting they may affect pre-mRNA splicing. In five (33, 7975, 1412, 6388 and 2660), the universally conserved GT and AG di-nucleotides are affected. The majority of intronic splice site mutations published so far are associated with DCM or LGMD1B (Chrestian, et al., 2008; Muchir, et al., 2000; Otomo, et al., 2005) while others have been

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

shown to result in EDMD (Bakay, et al., 2006). In our study however, all patients with intronic splice site mutations presented with an EDMD phenotype (Table 2). We also had three patients with mutations located on either the first nucleotide of exon 2 or the last nucleotide of exon 4. Patient 2018, who presented with DCM, and patient 778, who presented with an EDMD phenotype with cardiac involvement, both had the last nucleotide of exon 4 mutated to an A (c.810G>A; p.K270K). In patient 91, who presented with an LGMD phenotype with cardiac involvement, the first nucleotide in exon 2 is mutated to a T (c.357C>T; p.R119R) (Figure 1A). Such mutation-types are very rare mutational events and only one other such mutation has been described so far in the *LMNA* gene. It is located on the last nucleotide of exon 2 (c.513G>A; p.K171K) and was found in four patients diagnosed with LGMD1B (Todorova, et al., 2003). mRNA analysis on these patients showed that this results in a partial skipping of the canonical 5' splice site in intron 2 and the alternative use of a cryptic GT donor site within intron 2 leading to an insertion of 15 additional amino acids between exon 2 and 3 (Todorova, et al., 2003).

Cells isolated from patients with *LMNA* mutations, or cells over-expressing mutant lamin A, often display aberrant localization of nuclear envelope proteins and changes in nuclear morphology. In our study, we observe both phenomena: constitutive lamin A-R25P and lamin A-R249W expression caused severe changes in nuclear shape and size, while lamin A-N456I and lamin A-R541P resulted in nuclear lamin A-positive foci. Nuclear foci staining for lamin A are frequently described when over-expressing mutant and lamin A-wild type *in vitro* (Bechert, et al., 2003; Holt, et al., 2001; Ostlund, et al., 2001). In contrast, such foci are not very common in primary cells isolated from patients with *LMNA* mutations (Emerson, et al., 2009; Markiewicz, et al., 2002; Muchir, et al., 2004; Taimen, et al., 2009; Vigouroux, et al., 2001; Zhang, et al., 2007), suggesting that lamin A-positive foci formation can be

1
2
3 attributed to lamin A over-expression. Patient fibroblasts that do show lamin A-positive foci
4
5 usually carry FPLD but also EDMD causing mutations in the Ig-fold domain (Capanni, et al.,
6
7 2003; Muchir, et al., 2004). We see similar effects using mouse C2C12 myogenic cells. Cells
8
9 expressing lamin A-R25P and lamin A-R249W do not form nuclear foci staining for lamin
10
11 A. However, constitutive expression of the lamin A variants with a mutation in the Ig-like
12
13 fold (lamin A-N456I) and adjacent to the Ig-like fold (lamin A-R41P) induces lamin A foci
14
15 formation in 25% and 10% of all infected nuclei respectively. Although nuclear foci appear
16
17 to be smaller in cells infected with lamin A-R541P, these results may suggest that the
18
19 molecular mechanism inducing these foci and perhaps the underlying disease mechanism, is
20
21 similar for the two mutations in the tail domain of lamin A analyzed in this study.
22
23
24
25
26
27
28

29
30 In contrast, constitutive lamin A-R25P and lamin A-R249W expression in mouse myogenic
31
32 cells caused severe changes in nuclear shape and size. Nuclear blebbing is a type of nuclear
33
34 distortion commonly found in progeria and other laminopathies (Eriksson, et al., 2003;
35
36 Goldman, et al., 2004; Jacob and Garg, 2006; Taimen, et al., 2009). Khatau et al. report that
37
38 the nuclear morphology can be regulated by a perinuclear actin cap which is disrupted in
39
40 cells from *lmna*^{-/-} and *lmna*^{L530P/L530P} mice (Khatau, et al., 2009). To test if the abnormal
41
42 nuclear morphology we observed was associated with a misarranged actin-cytoskeleton, we
43
44 stained infected C2C12 cells for F-actin. However, while there were perturbed F-actin stress
45
46 fibres with lamin A-R25P, as has been described previously for other mutations in patient
47
48 fibroblasts (Emerson, et al., 2009), confocal imaging did not reveal differences in the
49
50 perinuclear actin cap associated with this, or any of our other mutant lamin A-species (data
51
52 not shown). This suggests that there might be other factors involved in nuclear deformation
53
54 in this case. One possibility of nuclear deformation is a misregulation of nesprin or other
55
56 members of the LINC complex which physically connects the nuclear lamin with the
57
58
59
60

cytoskeleton (Razafsky and Hodzic, 2009). The expression pattern of these interaction partners will be the subject of future investigations.

Interestingly, aberrant nuclear morphology in both mutants (lamin A-R25P and lamin A-R249W) is accompanied by a polar loss of lamin B expression in approximately 20-30% of nuclei. The same phenomenon has been observed by others in cells from HGPS patients with the p.E145K mutation (Taimen, et al., 2009) and in fibroblasts isolated from FPLD patients (Vigouroux, et al., 2001). Mouse embryonic fibroblasts from mouse embryos homozygous for a truncated, non-functional form of lamin B1 show severely misshaped nuclei too, suggesting that the loss of lamin B1 is a causative event for the observed nuclear lobulation (Vergnes, et al., 2004). How mutated lamin A affects lamin B localization is unclear and if a correction of lamin B expression can restore a normal nuclear morphology remains to be determined. It would also be very interesting to see if there are any *LMNA* single nucleotide polymorphisms (SNPs) that can affect lamin B localization and nuclear morphology.

Generally, patient fibroblasts with mutations associated with severe forms of laminopathies such as MAD (p.L59R, p.R527C, p.R527H) (Agarwal, et al., 2008; Nguyen, et al., 2007; Novelli, et al., 2002), WRN (p.R133L, p.L140R) (Caux, et al., 2003; Chen, et al., 2003) and FPLD (p.R439C) (Verstraeten, et al., 2009) all show the most profound changes in nuclear morphology. Taimen et al. have shown that nuclei of dermal fibroblast isolated from HGPS patients with the lamin A-E145K mutation show drastic changes in morphology and are severely lobulated (Taimen, et al., 2009). It has been suggested that the underlying mechanism of the pathogenicity of HGPS causing lamin A-E145K is a disrupted filament formation (Taimen, et al., 2009). However, mutant lamin A variants that caused an effect on nuclear morphology in our study result in either typical EDMD2 (lamin A-R25P) or an early

onset/L-CMD phenotype (lamin A-R249W), but whether they affect filament formation to differing degrees is unknown.

A-type lamins are expressed in mouse satellite cells: the resident stem cells of skeletal muscle (Gnocchi, et al., 2009). Therefore perturbed lamin function does not only affect the myonuclei of muscle fibres, but could also compromise satellite cell-mediated muscle maintenance and repair. A disrupted nuclear morphology is likely to affect basic cellular processes, such as proliferation and differentiation of myoblasts (Gnocchi, et al., 2008). It is generally accepted that mutations in lamin A can affect cell cycle kinetics (Emerson, et al., 2009; Johnson, et al., 2004). Fibroblasts from HGPS patients demonstrate a decreased cell growth rate (Goldman, et al., 2004) and fibroblasts isolated from EDMD but not DCM patients have been shown to have an increase in cell proliferation (Emerson, et al., 2009). However, it has also been reported that cell cycle progression is dependent on nuclear size (Roca-Cusachs, et al., 2008; Yen and Pardee, 1979). It is therefore likely that cells expressing lamin A-R25P and lamin A-R249W show altered cell cycle progression and proliferation.

In conclusion, we describe 15 novel *LMNA* mutations that underlie a striated muscle phenotype, increasing the mutation spectrum by ~6%. These will contribute towards formulating more accurate genotype-phenotype correlations in the laminopathies. Our analysis of 4 *LMNA* mutations shows that those located in the central rod domain perturb lamin B polarization and nuclear morphology, whilst mutations in the Ig-like fold domain increase lamin A-positive nuclear foci. We conclude that although the molecular mechanisms underlying the *LMNA*-generated pathogenic cascade in a particular tissue, with respect to intrinsic cellular processes such as cell cycle and cell signalling etc., may be similar for a given laminopathy, the disease penetrance and clinical variability within a phenotype may

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

arise from the combined contribution of genetic background, digenism and environmental factors.

Acknowledgements

This work was supported by grant No. A6356678101 from the Muscular Dystrophy Association, awarded to JAE and CAB. JS was partially funded by the MYORES Network of Excellence (contract 511978) from the European Commission 6th Framework Programme, VFG was funded by The Medical Research Council (grant G0700307). The laboratory of PSZ is also supported by The Muscular Dystrophy Campaign, the Association of International Cancer Research, Association Française contre les Myopathies, The Wellcome Trust and OPTISTEM (contract 223098), through the European Union 7th Framework Programme.

References

- Agarwal AK, Kazachkova I, Ten S, Garg A. 2008. Severe mandibuloacral dysplasia-associated lipodystrophy and progeria in a young girl with a novel homozygous Arg527Cys LMNA mutation. *J Clin Endocrinol Metab* 93(12):4617-23.
- Arbustini EA, Pasotti M, Pilotto A, Repetto A, Grasso M, Diegoli M. 2005. Gene symbol: CMD1A. Disease: Dilated cardiomyopathy associated with conduction system disease. *Hum Genet* 117(2-3):295.
- Bakay M, Wang Z, Melcon G, Schiltz L, Xuan J, Zhao P, Sartorelli V, Seo J, Pegoraro E, Angelini C and others. 2006. Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration. *Brain* 129(Pt 4):996-1013.
- Bechert K, Lagos-Quintana M, Harborth J, Weber K, Osborn M. 2003. Effects of expressing lamin A mutant protein causing Emery-Dreifuss muscular dystrophy and familial partial lipodystrophy in HeLa cells. *Exp Cell Res* 286(1):75-86.
- Ben Yaou R, Toutain A, Arimura T, Demay L, Massart C, Peccate C, Muchir A, Llense S, Deburgrave N, Leturcq F and others. 2007. Multitissular involvement in a family with LMNA and EMD mutations: Role of digenic mechanism? *Neurology* 68(22):1883-94.
- Benedetti S, Menditto I, Degano M, Rodolico C, Merlini L, D'Amico A, Palmucci L, Berardinelli A, Pegoraro E, Trevisan CP and others. 2007. Phenotypic clustering of lamin A/C mutations in neuromuscular patients. *Neurology* 69(12):1285-92.
- Bione S, Maestrini E, Rivella S, Mancini M, Regis S, Romeo G, Toniolo D. 1994. Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. *Nat Genet* 8(4):323-7.
- Bonne G, Di Barletta MR, Varnous S, Becane HM, Hammouda EH, Merlini L, Muntoni F, Greenberg CR, Gary F, Urtizberea JA and others. 1999. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. *Nat Genet* 21(3):285-8.
- Bonne G, Mercuri E, Muchir A, Urtizberea A, Becane HM, Recan D, Merlini L, Wehnert M, Boor R, Reuner U and others. 2000. Clinical and molecular genetic spectrum of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the lamin A/C gene. *Ann Neurol* 48(2):170-80.
- Bonne G, Yaou RB, Beroud C, Boriani G, Brown S, de Visser M, Duboc D, Ellis J, Hausmanowa-Petrusewicz I, Lattanzi G and others. 2003. 108th ENMC International Workshop, 3rd Workshop of the MYO-CLUSTER project: EUROMEN, 7th International Emery-Dreifuss Muscular Dystrophy (EDMD) Workshop, 13-15 September 2002, Naarden, The Netherlands. *Neuromuscul Disord* 13(6):508-15.

- Boriani G, Gallina M, Merlini L, Bonne G, Toniolo D, Amati S, Biffi M, Martignani C, Frabetti L, Bonvicini M and others. 2003. Clinical relevance of atrial fibrillation/flutter, stroke, pacemaker implant, and heart failure in Emery-Dreifuss muscular dystrophy: a long-term longitudinal study. *Stroke* 34(4):901-8.
- Brette S, Penisson-Besnier I, Dupuis JM, Bonne G, Victor J. 2004. [Cardiac manifestations of laminopathies]. *Arch Mal Coeur Vaiss* 97(10):973-7.
- Broers JL, Ramaekers FC, Bonne G, Yaou RB, Hutchison CJ. 2006. Nuclear lamins: laminopathies and their role in premature ageing. *Physiol Rev* 86(3):967-1008.
- Brown CA, Lanning RW, McKinney KQ, Salvino AR, Cherniske E, Crowe CA, Darras BT, Gominak S, Greenberg CR, Grosmann C and others. 2001. Novel and recurrent mutations in lamin A/C in patients with Emery-Dreifuss muscular dystrophy. *Am J Med Genet* 102(4):359-67.
- Capanni C, Cenni V, Mattioli E, Sabatelli P, Ognibene A, Columbaro M, Parnaik VK, Wehnert M, Maraldi NM, Squarzoni S and others. 2003. Failure of lamin A/C to functionally assemble in R482L mutated familial partial lipodystrophy fibroblasts: altered intermolecular interaction with emerin and implications for gene transcription. *Exp Cell Res* 291(1):122-34.
- Carboni N, Mura M, Marrosu G, Cocco E, Ahmad M, Solla E, Mateddu A, Maioli MA, Marini S, Nissardi V and others. 2008. Muscle MRI findings in patients with an apparently exclusive cardiac phenotype due to a novel LMNA gene mutation. *Neuromuscul Disord* 18(4):291-8.
- Caux F, Dubosclard E, Lascols O, Buendia B, Chazouilleres O, Cohen A, Courvalin JC, Laroche L, Capeau J, Vigouroux C and others. 2003. A new clinical condition linked to a novel mutation in lamins A and C with generalized lipoatrophy, insulin-resistant diabetes, disseminated leukomelanodermic papules, liver steatosis, and cardiomyopathy. *J Clin Endocrinol Metab* 88(3):1006-13.
- Chen L, Lee L, Kudlow BA, Dos Santos HG, Sletvold O, Shafeghati Y, Botha EG, Garg A, Hanson NB, Martin GM and others. 2003. LMNA mutations in atypical Werner's syndrome. *Lancet* 362(9382):440-5.
- Chrestian N, Valdmanis PN, Echahidi N, Brunet D, Bouchard JP, Gould P, Rouleau GA, Champagne J, Dupre N. 2008. A novel mutation in a large French-Canadian family with LGMD1B. *Can J Neurol Sci* 35(3):331-4.
- Clements L, Manilal S, Love DR, Morris GE. 2000. Direct interaction between emerin and lamin A. *Biochem Biophys Res Commun* 267(3):709-14.
- Colomer J, Iturriaga C, Bonne G, Schwartz K, Manilal S, Morris GE, Puche M, Fernandez-Alvarez E. 2002. Autosomal dominant Emery-Dreifuss muscular dystrophy: a new family with late diagnosis. *Neuromuscul Disord* 12(1):19-25.

- 1
2
3 Csoka AB, Cao H, Sammak PJ, Constantinescu D, Schatten GP, Hegele RA. 2004. Novel
4 lamin A/C gene (LMNA) mutations in atypical progeroid syndromes. *J Med Genet*
5 41(4):304-8.
6
7
8
9 De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, Lyonnet S,
10 Stewart CL, Munnich A, Le Merrer M and others. 2003. Lamin a truncation in
11 Hutchinson-Gilford progeria. *Science* 300(5628):2055.
12
13 De Sandre-Giovannoli A, Chaouch M, Kozlov S, Vallat JM, Tazir M, Kassouri N,
14 Szeppetowski P, Hammadouche T, Vandenberghe A, Stewart CL and others. 2002.
15 Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause
16 autosomal recessive axonal neuropathy in human (Charcot-Marie-Tooth disorder type
17 2) and mouse. *Am J Hum Genet* 70(3):726-36.
18
19
20
21 Ellis JA, Craxton M, Yates JR, Kendrick-Jones J. 1998. Aberrant intracellular targeting and
22 cell cycle-dependent phosphorylation of emerin contribute to the Emery-Dreifuss
23 muscular dystrophy phenotype. *J Cell Sci* 111 (Pt 6):781-92.
24
25
26 Emerson LJ, Holt MR, Wheeler MA, Wehnert M, Parsons M, Ellis JA. 2009. Defects in cell
27 spreading and ERK1/2 activation in fibroblasts with lamin A/C mutations. *Biochim*
28 *Biophys Acta* 1792(8):810-21.
29
30
31 Emery AE. 1989. Emery-Dreifuss syndrome. *J Med Genet* 26(10):637-41.
32
33
34 Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM,
35 Moses TY, Berglund P and others. 2003. Recurrent de novo point mutations in lamin
36 A cause Hutchinson-Gilford progeria syndrome. *Nature* 423(6937):293-8.
37
38
39 Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M, Atherton J, Vidaillet HJ,
40 Jr., Spudich S, De Girolami U and others. 1999. Missense mutations in the rod
41 domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-
42 system disease. *N Engl J Med* 341(23):1715-24.
43
44
45 Felice KJ, Schwartz RC, Brown CA, Leicher CR, Grunnet ML. 2000. Autosomal dominant
46 Emery-Dreifuss dystrophy due to mutations in rod domain of the lamin A/C gene.
47 *Neurology* 55(2):275-80.
48
49
50
51 Fidzianska A, Glinka Z. 2006. Rimmed vacuoles with beta-amyloid and tau protein deposits
52 in the muscle of children with hereditary myopathy. *Acta Neuropathol* 112(2):185-93.
53
54 Fokkema IF, den Dunnen JT, Taschner PE. 2005. LOVD: easy creation of a locus-specific
55 sequence variation database using an "LSDB-in-a-box" approach. *Hum Mutat*
56 26(2):63-8.
57
58
59 Genschel J, Bochow B, Kuepferling S, Ewert R, Hetzer R, Lochs H, Schmidt H. 2001. A
60 R644C mutation within lamin A extends the mutations causing dilated
cardiomyopathy. *Hum Mutat* 17(2):154.

- Gnocchi VF, Ellis JA, Zammit PS. 2008. Does satellite cell dysfunction contribute to disease progression in Emery-Dreifuss muscular dystrophy? *Biochem Soc Trans* 36(Pt 6):1344-9.
- Gnocchi VF, White RB, Ono Y, Ellis JA, Zammit PS. 2009. Further characterisation of the molecular signature of quiescent and activated mouse muscle satellite cells. *PLoS One* 4(4):e5205.
- Goldman RD, Shumaker DK, Erdos MR, Eriksson M, Goldman AE, Gordon LB, Gruenbaum Y, Khuon S, Mendez M, Varga R and others. 2004. Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. *Proc Natl Acad Sci U S A* 101(24):8963-8.
- Golzio PG, Chiribiri A, Gaita F. 2007. 'Unexpected' sudden death avoided by implantable cardioverter defibrillator in Emery Dreifuss patient. *Europace* 9(12):1158-60.
- Gueneau L, Bertrand AT, Jais JP, Salih MA, Stojkovic T, Wehnert M, Hoeltzenbein M, Spuler S, Saitoh S, Verschueren A and others. 2009. Mutations of the FHL1 gene cause Emery-Dreifuss muscular dystrophy. *Am J Hum Genet* 85(3):338-53.
- Hegele RA, Anderson CM, Cao H. 2000. Lamin A/C mutation in a woman and her two daughters with Dunnigan-type partial lipodystrophy and insulin resistance. *Diabetes Care* 23(2):258-9.
- Holt I, Clements L, Manilal S, Brown SC, Morris GE. 2001. The R482Q lamin A/C mutation that causes lipodystrophy does not prevent nuclear targeting of lamin A in adipocytes or its interaction with emerin. *Eur J Hum Genet* 9(3):204-8.
- Holt I, Ostlund C, Stewart CL, Man N, Worman HJ, Morris GE. 2003. Effect of pathogenic mis-sense mutations in lamin A on its interaction with emerin in vivo. *J Cell Sci* 116(Pt 14):3027-35.
- Jacob KN, Garg A. 2006. Laminopathies: multisystem dystrophy syndromes. *Mol Genet Metab* 87(4):289-302.
- Johnson BR, Nitta RT, Frock RL, Mounkes L, Barbie DA, Stewart CL, Harlow E, Kennedy BK. 2004. A-type lamins regulate retinoblastoma protein function by promoting subnuclear localization and preventing proteasomal degradation. *Proc Natl Acad Sci U S A* 101(26):9677-82.
- Khatau SB, Hale CM, Stewart-Hutchinson PJ, Patel MS, Stewart CL, Searson PC, Hodzic D, Wirtz D. 2009. A perinuclear actin cap regulates nuclear shape. *Proc Natl Acad Sci U S A* 106(45):19017-22.
- Ki CS, Hong JS, Jeong GY, Ahn KJ, Choi KM, Kim DK, Kim JW. 2002. Identification of lamin A/C (LMNA) gene mutations in Korean patients with autosomal dominant

- Emery-Dreifuss muscular dystrophy and limb-girdle muscular dystrophy 1B. *J Hum Genet* 47(5):225-8.
- Kichuk Chrisant MR, Drummond-Webb J, Hallowell S, Friedman NR. 2004. Cardiac transplantation in twins with autosomal dominant Emery-Dreifuss muscular dystrophy. *J Heart Lung Transplant* 23(4):496-8.
- Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227(5259):680-5.
- Lee KK, Haraguchi T, Lee RS, Koujin T, Hiraoka Y, Wilson KL. 2001. Distinct functional domains in emerin bind lamin A and DNA-bridging protein BAF. *J Cell Sci* 114(Pt 24):4567-73.
- Lin F, Worman HJ. 1993. Structural organization of the human gene encoding nuclear lamin A and nuclear lamin C. *J Biol Chem* 268(22):16321-6.
- Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. *J Biol Chem* 193(1):265-75.
- Markiewicz E, Venables R, Mauricio Alvarez R, Quinlan R, Dorobek M, Hausmanowa-Petruciewicz I, Hutchison C. 2002. Increased solubility of lamins and redistribution of lamin C in X-linked Emery-Dreifuss muscular dystrophy fibroblasts. *J Struct Biol* 140(1-3):241-53.
- McGrath MJ, Cottle DL, Nguyen MA, Dyson JM, Coghill ID, Robinson PA, Holdsworth M, Cowling BS, Hardeman EC, Mitchell CA and others. 2006. Four and a half LIM protein 1 binds myosin-binding protein C and regulates myosin filament formation and sarcomere assembly. *J Biol Chem* 281(11):7666-83.
- Mercuri E, Brown SC, Nihoyannopoulos P, Poulton J, Kinali M, Richard P, Piercy RJ, Messina S, Sewry C, Burke MM and others. 2005. Extreme variability of skeletal and cardiac muscle involvement in patients with mutations in exon 11 of the lamin A/C gene. *Muscle Nerve* 31(5):602-9.
- Mercuri E, Poppe M, Quinlivan R, Messina S, Kinali M, Demay L, Bourke J, Richard P, Sewry C, Pike M and others. 2004. Extreme variability of phenotype in patients with an identical missense mutation in the lamin A/C gene: from congenital onset with severe phenotype to milder classic Emery-Dreifuss variant. *Arch Neurol* 61(5):690-4.
- Meune C, Van Berlo JH, Anselme F, Bonne G, Pinto YM, Duboc D. 2006. Primary prevention of sudden death in patients with lamin A/C gene mutations. *N Engl J Med* 354(2):209-10.
- Motsch I, Kaluarachchi M, Emerson LJ, Brown CA, Brown SC, Dabauvalle MC, Ellis JA. 2005. Lamins A and C are differentially dysfunctional in autosomal dominant Emery-Dreifuss muscular dystrophy. *Eur J Cell Biol* 84(9):765-81.

- Muchir A, Bonne G, van der Kooi AJ, van Meegen M, Baas F, Bolhuis PA, de Visser M, Schwartz K. 2000. Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B). *Hum Mol Genet* 9(9):1453-9.
- Muchir A, Medioni J, Laluc M, Massart C, Arimura T, van der Kooi AJ, Desguerre I, Mayer M, Ferrer X, Briault S and others. 2004. Nuclear envelope alterations in fibroblasts from patients with muscular dystrophy, cardiomyopathy, and partial lipodystrophy carrying lamin A/C gene mutations. *Muscle Nerve* 30(4):444-50.
- Muntoni F, Bonne G, Goldfarb LG, Mercuri E, Piercy RJ, Burke M, Yaou RB, Richard P, Recan D, Shatunov A and others. 2006. Disease severity in dominant Emery Dreifuss is increased by mutations in both emerin and desmin proteins. *Brain* 129(Pt 5):1260-8.
- Nguyen D, Leistritz DF, Turner L, MacGregor D, Ohson K, Dancey P, Martin GM, Oshima J. 2007. Collagen expression in fibroblasts with a novel LMNA mutation. *Biochem Biophys Res Commun* 352(3):603-8.
- Novelli G, Muchir A, Sangiuolo F, Helbling-Leclerc A, D'Apice MR, Massart C, Capon F, Sbraccia P, Federici M, Lauro R and others. 2002. Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. *Am J Hum Genet* 71(2):426-31.
- Onishi Y, Higuchi J, Ogawa T, Namekawa A, Hayashi H, Odakura H, Goto K, Hayashi YK. 2002. [The first Japanese case of autosomal dominant Emery-Dreifuss muscular dystrophy with a novel mutation in the lamin A/C gene]. *Rinsho Shinkeigaku* 42(2):140-4.
- Ostlund C, Bonne G, Schwartz K, Worman HJ. 2001. Properties of lamin A mutants found in Emery-Dreifuss muscular dystrophy, cardiomyopathy and Dunnigan-type partial lipodystrophy. *J Cell Sci* 114(Pt 24):4435-45.
- Otomo J, Kure S, Shiba T, Karibe A, Shinozaki T, Yagi T, Naganuma H, Tezuka F, Miura M, Ito M and others. 2005. Electrophysiological and histopathological characteristics of progressive atrioventricular block accompanied by familial dilated cardiomyopathy caused by a novel mutation of lamin A/C gene. *J Cardiovasc Electrophysiol* 16(2):137-45.
- Pasotti M, Klersy C, Pilotto A, Marziliano N, Rapezzi C, Serio A, Mannarino S, Gambarin F, Favalli V, Grasso M and others. 2008. Long-term outcome and risk stratification in dilated cardiomyopathies. *J Am Coll Cardiol* 52(15):1250-60.
- Perrot A, Hussein S, Ruppert V, Schmidt HH, Wehnert MS, Duong NT, Posch MG, Panek A, Dietz R, Kindermann I and others. 2009. Identification of mutational hot spots in LMNA encoding lamin A/C in patients with familial dilated cardiomyopathy. *Basic Res Cardiol* 104(1):90-9.

- Prokocimer M, Davidovich M, Nissim-Rafinia M, Wiesel-Motiuk N, Bar D, Barkan R, Meshorer E, Gruenbaum Y. 2009. Nuclear lamins: key regulators of nuclear structure and activities. *J Cell Mol Med*.
- Quijano-Roy S, Mbieleu B, Bonnemann CG, Jeannet PY, Colomer J, Clarke NF, Cuisset JM, Roper H, De Meirleir L, D'Amico A and others. 2008. De novo LMNA mutations cause a new form of congenital muscular dystrophy. *Ann Neurol* 64(2):177-86.
- Raffaele Di Barletta M, Ricci E, Galluzzi G, Tonali P, Mora M, Morandi L, Romorini A, Voit T, Orstavik KH, Merlini L and others. 2000. Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy. *Am J Hum Genet* 66(4):1407-12.
- Rankin J, Auer-Grumbach M, Bagg W, Colclough K, Nguyen TD, Fenton-May J, Hattersley A, Hudson J, Jardine P, Josifova D and others. 2008. Extreme phenotypic diversity and nonpenetrance in families with the LMNA gene mutation R644C. *Am J Med Genet A* 146A(12):1530-42.
- Razafsky D, Hodzic D. 2009. Bringing KASH under the SUN: the many faces of nucleocytoplasmic connections. *J Cell Biol* 186(4):461-72.
- Richardson JS, Richardson DC. 1988. Amino acid preferences for specific locations at the ends of alpha helices. *Science* 240(4859):1648-52.
- Roca-Cusachs P, Alcaraz J, Sunyer R, Samitier J, Farre R, Navajas D. 2008. Micropatterning of single endothelial cell shape reveals a tight coupling between nuclear volume in G1 and proliferation. *Biophys J* 94(12):4984-95.
- Rudenskaya GE, Polyakov AV, Tverskaya SM, Zaklyazminskaya EV, Chukhrova AL, Groznova OE, Ginter EK. 2008. Laminopathies in Russian families. *Clin Genet* 74(2):127-33.
- Scharner J, Gnocchi VF, Ellis JA, Zammit PS. 2010. Genotype-phenotype correlations in laminopathies: how does fate translate? *Biochem Soc Trans* 38(Pt 1):257-62.
- Schirmer EC, Foisner R. 2007. Proteins that associate with lamins: many faces, many functions. *Exp Cell Res* 313(10):2167-79.
- Shackleton S, Lloyd DJ, Jackson SN, Evans R, Niermeijer MF, Singh BM, Schmidt H, Brabant G, Kumar S, Durrington PN and others. 2000. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. *Nat Genet* 24(2):153-6.
- Shen JJ, Brown CA, Lupski JR, Potocki L. 2003. Mandibuloacral dysplasia caused by homozygosity for the R527H mutation in lamin A/C. *J Med Genet* 40(11):854-7.

- Simha V, Agarwal AK, Oral EA, Fryns JP, Garg A. 2003. Genetic and phenotypic heterogeneity in patients with mandibuloacral dysplasia-associated lipodystrophy. *J Clin Endocrinol Metab* 88(6):2821-4.
- Speckman RA, Garg A, Du F, Bennett L, Veile R, Arioglu E, Taylor SI, Lovett M, Bowcock AM. 2000. Mutational and haplotype analyses of families with familial partial lipodystrophy (Dunnigan variety) reveal recurrent missense mutations in the globular C-terminal domain of lamin A/C. *Am J Hum Genet* 66(4):1192-8.
- Sylvius N, Bilinska ZT, Veinot JP, Fidzianska A, Bolongo PM, Poon S, McKeown P, Davies RA, Chan KL, Tang AS and others. 2005. In vivo and in vitro examination of the functional significances of novel lamin gene mutations in heart failure patients. *J Med Genet* 42(8):639-47.
- Szeverenyi I, Ramamoorthy R, Teo ZW, Luan HF, Ma ZG, Ramachandran S. 2006. Large-scale systematic study on stability of the Ds element and timing of transposition in rice. *Plant Cell Physiol* 47(1):84-95.
- Taimen P, Pflieghaar K, Shimi T, Moller D, Ben-Harush K, Erdos MR, Adam SA, Herrmann H, Medalia O, Collins FS and others. 2009. A progeria mutation reveals functions for lamin A in nuclear assembly, architecture, and chromosome organization. *Proc Natl Acad Sci U S A*.
- Todorova A, Halliger-Keller B, Walter MC, Dabauvalle MC, Lochmuller H, Muller CR. 2003. A synonymous codon change in the LMNA gene alters mRNA splicing and causes limb girdle muscular dystrophy type 1B. *J Med Genet* 40(10):e115.
- van der Kooi AJ, Bonne G, Eymard B, Duboc D, Talim B, Van der Valk M, Reiss P, Richard P, Demay L, Merlini L and others. 2002. Lamin A/C mutations with lipodystrophy, cardiac abnormalities, and muscular dystrophy. *Neurology* 59(4):620-3.
- van Tintelen JP, Hofstra RM, Katerberg H, Rossenbacker T, Wiesfeld AC, du Marchie Sarvaas GJ, Wilde AA, van Langen IM, Nannenberg EA, van der Kooi AJ and others. 2007. High yield of LMNA mutations in patients with dilated cardiomyopathy and/or conduction disease referred to cardiogenetics outpatient clinics. *Am Heart J* 154(6):1130-9.
- Vaughan A, Alvarez-Reyes M, Bridger JM, Broers JL, Ramaekers FC, Wehnert M, Morris GE, Whitfield WGF, Hutchison CJ. 2001. Both emerin and lamin C depend on lamin A for localization at the nuclear envelope. *J Cell Sci* 114(Pt 14):2577-90.
- Vergnes L, Peterfy M, Bergo MO, Young SG, Reue K. 2004. Lamin B1 is required for mouse development and nuclear integrity. *Proc Natl Acad Sci U S A* 101(28):10428-33.
- Verstraeten VL, Broers JL, Ramaekers FC, van Steensel MA. 2007. The nuclear envelope, a key structure in cellular integrity and gene expression. *Curr Med Chem* 14(11):1231-48.

- Verstraeten VL, Caputo S, van Steensel MA, Duband-Goulet I, Zinn-Justin S, Kamps M, Kuijpers HJ, Ostlund C, Worman HJ, Briede JJ and others. 2009. The R439C mutation in LMNA causes lamin oligomerization and susceptibility to oxidative stress. *J Cell Mol Med* 13(5):959-71.
- Vigouroux C, Auclair M, Dubosclard E, Pouchelet M, Capeau J, Courvalin JC, Buendia B. 2001. Nuclear envelope disorganization in fibroblasts from lipodystrophic patients with heterozygous R482Q/W mutations in the lamin A/C gene. *J Cell Sci* 114(Pt 24):4459-68.
- Vytopil M, Benedetti S, Ricci E, Galluzzi G, Dello Russo A, Merlini L, Boriani G, Gallina M, Morandi L, Politano L and others. 2003. Mutation analysis of the lamin A/C gene (LMNA) among patients with different cardiomyopathic phenotypes. *J Med Genet* 40(12):e132.
- Vytopil M, Ricci E, Dello Russo A, Hanisch F, Neudecker S, Zierz S, Ricotti R, Demay L, Richard P, Wehnert M and others. 2002. Frequent low penetrance mutations in the Lamin A/C gene, causing Emery Dreifuss muscular dystrophy. *Neuromuscul Disord* 12(10):958-63.
- Wagner N, Krohne G. 2007. LEM-Domain proteins: new insights into lamin-interacting proteins. *Int Rev Cytol* 261:1-46.
- Yen A, Pardee AB. 1979. Role of nuclear size in cell growth initiation. *Science* 204(4399):1315-7.
- Young J, Morbois-Trabut L, Couzinet B, Lascols O, Dion E, Bereziat V, Fève B, Richard I, Capeau J, Chanson P and others. 2005. Type A insulin resistance syndrome revealing a novel lamin A mutation. *Diabetes* 54(6):1873-8.
- Zammit PS, Relaix F, Nagata Y, Ruiz AP, Collins CA, Partridge TA, Beauchamp JR. 2006. Pax7 and myogenic progression in skeletal muscle satellite cells. *J Cell Sci* 119(Pt 9):1824-32.
- Zhang Q, Bethmann C, Worth NF, Davies JD, Wasner C, Feuer A, Ragnauth CD, Yi Q, Mellad JA, Warren DT and others. 2007. Nesprin-1 and -2 are involved in the pathogenesis of Emery Dreifuss muscular dystrophy and are critical for nuclear envelope integrity. *Hum Mol Genet* 16(23):2816-33.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure Legends

Figure 1. Schematic of the *LMNA* gene and lamin A protein indicating mutations

(A) Schematic of the *LMNA* gene and lamin A protein. Lamin A is encoded by exons 1-12 while lamin C terminates at exon 10 with 6 unique amino acids at its C-terminal. The alternative splice site for lamin A is indicated. Sequence variations affecting splice donor or acceptor sites which lead to disease are shown for IVS 4, 6, 7 and 8. Missense mutations, insertions and deletions are indicated on the lamin A protein, where the head, central rod and tail domain (incorporating the nuclear localisation signal (NLS), and Ig-like fold) are indicated. Novel sequence variants are shown above the gene/protein (red) and mutations used for *in vitro* investigation are underlined (blue), while recurring mutations are shown beneath the gene/protein. Table 1 provides a detailed genetic description of the sequence variants. (B) Illustration of evolutionary conservation of residues associated with novel missense mutations, insertions and deletions located in the coding region of *LMNA* and those used in our *in vitro* analysis (blue/underlined). Sequences were obtained from the online databank swissprot (<http://expasy.org/sprot/>) and aligned with the online tool ClustalW2 (<http://www.ebi.ac.uk/clustalw/>). Partial sequence only, with // denoting non-consecutive sequence, * indicating identical residues in all aligned sequences; ‘:’ showing conserved substitutions; and ‘.’ marking semi-conserved substitutions. If viewed in colour: residues with nonpolar side chains are indicated in red, acidic residues are shown in blue, basic residues shown in magenta and amino acids with uncharged polar side chains are indicated in green.

Figure 2. Mutant lamin A species affect nuclear size and shape in myogenic cells

(A) Proliferating mouse C2C12 cells infected with control pMSCV-laminA-IRES-eGFP encoding wild type lamin A-IRES-eGFP and immunostained for eGFP and lamin A. Cells

expressing high levels of GFP show a increased expression of lamin A-wild type (arrowheads) compared to cells expressing low levels of GFP (arrows); Scale bar 100 μ m. (B) Western blot of uninfected C2C12 cells and cells infected with *pMSCV-IRES-eGFP* (RV control), *pMSCV-laminA-IRES-eGFP* (Lamin A), *pMSCV-laminA-R25P-IRES-eGFP* (R25P), *pMSCV-laminA-R249W-IRES-eGFP* (R249W), *pMSCV-laminA-N456I-IRES-eGFP* (N456I) and *pMSCV-laminA-R541P-IRES-eGFP* (R541P). A representative blot probed for lamin A/C (N19) is shown. The relative quantities of lamin A normalized to β -tubulin are shown below, and range from 1.5 – 1.7 fold endogenous lamin A levels in the RV control sample. The endogenous level of lamin C does not change with constitutive expression of wild-type lamin A or the mutant forms. (C) Schematic of the *pMSCV-laminA-IRES-EGFP* vector used in this study, indicating the 5' and 3' long terminal repeats (LTR), Ψ packaging signal, the lamin A (wild type or mutant versions) and eGFP cDNAs, separated by an internal ribosome entry site (IRES). (D) Nuclear size (cross-sectional area) of cells with lamin A-R25P and lamin A-R249W increased by 29% $\pm$ 3.3% and 34% $\pm$ 4.5% respectively, compared to lamin A-wild type infected cells. (E) The contour ratio was significantly decreased in nuclei of cells expressing lamin A-R25P (0.87 $\pm$ 0.006) and lamin A-R249W (0.85 $\pm$ 0.007), but not with the other two mutant lamin A species. Values represent the mean $\pm$ SEM; * p <0.05; ** p <0.01 compared to lamin A-wild type infected cells.

Figure 3. Distribution of nuclear envelope-associated components in myogenic cells infected with mutant lamin A

Cells infected with *pMSCV-IRES-eGFP* (RV control), *pMSCV-laminA-IRES-eGFP* (Lamin A), *pMSCV-laminA-R25P-IRES-eGFP* (R25P), *pMSCV-laminA-R249W-IRES-eGFP* (R249W), *pMSCV-laminA-N456I-IRES-eGFP* (N456I) and *pMSCV-laminA-R541P-IRES-eGFP* (R541P) were immunostained for nuclear envelope components (lamin A, lamin A/C,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

lamin B, emerin; Scale bar = 10µm) and F-actin (red) (eGFP positive infected cells are indicated by arrowheads; Scale bar = 50µm). A representative selection of nuclei and cells are shown. Lamin A-positive nuclear speckles and lamin A capping (arrows) as well as a loss of lamin B from nuclear poles was evident to varying degrees in a mutant-dependent fashion. The localization of emerin is normal in all instances.

Figure 4. Nuclear abnormalities in myogenic cells infected with mutant lamin A

(A) Prominent lamin A foci distributed throughout the nucleus were frequently observed in cells infected with lamin A-N456I and lamin A-R541P. Nuclei with representative lamin A foci are shown. Scale bar = 10µm. (B) The fluorescence intensity of DAPI and lamin A along the central axis indicated by a dashed line is shown in the adjacent histogram. (C) Quantification of nuclei with prominent lamin A foci distributed throughout the nucleus. Values represent the mean ± SEM; * $p<0.05$, ** $p<0.01$ compared to wild type lamin A infected cells (wild type). (D) Loss of lamin B expression from one or multiple poles is frequently observed in cells expressing lamin A-R25P and lamin A-R249W. Scale bar = 10µm. (E) The fluorescence intensity of DAPI and lamin B along the central axis indicated by a dashed line is shown in the histogram. (F) Quantification of nuclei where a polar loss of lamin B expression was observed. Values represent the mean ± SEM; * $p<0.05$, ** $p<0.01$ compared to wild type lamin A infected cells.

Table 1: List of primers used for PCR and sequencing

Exon	Primer Name	Sequence (5'- 3')
1	1F*†	5'-TCTCTGTCCTTCGACCCGAG-3'
	1R*†	5'-CCTCTCCACTCCCCGCCA-3'
2	2F*†	5'- ACAGACTCCTTCTCTTAAATCTAC-3'
	2R*†	5'-GTAGAAGAGTGAGTGTACATGTG-3'
3	3F*†	5'-ACCTCTCAGCTTCCTTCAAGTT-3'
	3R†	5'-CTAGCCCAGCCCAAGTCTGT-3'
4	4F†	5'-GCCTCCCAGGAACTAATTCTG-3'
	4R*†	5'-CGTGGGTAAGGGTAGGGCTG-3'
5	5F*†	5'-ATGCCCAACTCAGGCCTGTG-3'
	5R†	5'-CGTTCAGCCTGCATCCGG-3'
6	6F†	5'-TCCCTCCTTCCCATACTTAG-3'
	6R†	5'-CCAGTTGCCGGGCCAGAG-3'
7	7F†	5'-CCCCACTTGGTCTCCCTCTCC-3'
	7R*†	5'-CCCTGATGCAGCTGTATCCCC-3'
8/9	8F*†	5'-CAAGATACACCCAAGAGCCTG-3'
	9R†	5'-CTCGTCCAGCAAGCAGCCAG-3'
10	10F†	5'-TCTTGTACAACCCTTCCCTGG-3'
	10R*†	5'-GGGTTCCCTGTTCAAGGTATA-3'
11	11F*†	5'-GTTGGGCCTGAGTGGTCAG-3'
	11R*†	5'-CACCTCGTCTACCCCTCG-3'
12	12F*†	5'-GGCTGGAGTGTGGAGGGATG-3'
	12R*†	5'-CCTCCCATGACGTGCAGGG-3'

* Primer used for PCR; † Primer used for sequencing

Table 2. Summary of clinical description of patients with *LMNA* mutations

ID#	<i>LMNA</i> mutation	Gender	Age of onset	Age of diagnosis	Origin	Skeletal muscle involvement	Contractures	Cardiac involvement	Other information
▼ Novel mutations									
91	p.R119R	M	Childhood	Died at age 45	Familial	Progressive proximal leg weakness; LGMD phenotype	Heel cord	Mild dilated cardiomyopathy; LVEF, 42% and cardiac conduction disease; pacemaker at age 33; died of heart failure at age 45	Weakness and pacemaker in mother; sudden cardiac death in brother (age 5); cardiac arrest (in 40's) in maternal grandfather, uncle and aunt
3734	p.R189P	M	10	33	Sporadic*	Limb-girdle, proximal upper	Neck and elbow (age 14)	Primary AV block and palpitations at age 22	n.a.
2952	p.R190dup	F	n.a.	30	Familial	Generalized	None	Atrial standstill, ventricular arrhythmia	n.a.
8542	p.F206L	M	n.a.	57	Familial	Generalized	n.a.	Cardiac conduction defect	n.a.
8434	p.S268P	M	n.a.	17	Familial	Proximal lower weakness	Elbow and achilles tendon	n.a.	n.a.
2018	p.K270K	M	n.a.	24	n.a.	n.a.	n.a.	Cardiomyopathy and conduction disorder	Initially diagnosed with BMD
778	p.K270K	M	5	26	Sporadic*	EDMD phenotype; Limb-girdle, proximal upper, distal lower	Elbow and ankle	Cardiac involvement age 25, prolonged PR-interval which slowly lengthened until at age 31 developed atrial fibrillation and cardiomyopathy; pacemaker at age 31	Muscle biopsy age 8 – myocyte apoptosis.
33 [†]	c.IVS4+1G>A (c.810+1G>A)	M	2	15	Familial	Proximal and distal weakness	Elbow, neck and rigid spine	n.a.	n.a.
6298	p.S295P	F	n.a.	47	Familial	Proximal weakness	Generalized	Cardiomyopathy with conduction system defects	n.a.
116	p.Q355del	F	n.a.	33	Familial	Atrophy of deltoid, triceps, trapezius and proximal legs muscles and calf hypertrophy	n.a.	First degree heart block at age 20; mild AV dysfunction on bundle studies	n.a.
2785	p.E361K	F	<5	12	Familial	EDMD phenotype	Ankle, achilles tendon and elbow	n.a.	Cardiomyopathy in mother who received a heart transplant
7975	c.IVS6-2A>G (c.1159-2A>G)	M	n.a.	41	Sporadic	EDMD phenotype; moderate proximal upper, distal lower and limb-girdle weakness	Elbow (severe), neck and ankle (minimal)	Cardiac conduction defect, pacemaker fitted	n.a.
342 [†]	p.G449D	M	2	9	Familial	Limb-girdle, proximal upper and distal lower weakness	Neck, elbow (age 3) and ankle (age 9)	n.a.	n.a.
9106	p.L454P	F	7	21	Sporadic	Limb-girdle, proximal upper and distal lower weakness	Ankle (age 7), elbow and neck (age 12)	Cardiac involvement at age 22	Non-ambulatory at age 14
7461 [†]	p.W467R	F	<3	5	Sporadic	Limb-girdle, proximal upper and distal lower weakness	Ankle (<age 3) and elbow (age 5)	n.a.	Clinical diagnosis of LGMD vs. CMD
2660	c.IVS8+1G>A (c.1488+1G>A)	M	n.a.	17	Sporadic	n.a.	n.a.	Pacemaker at age 24 which was replaced at age 30	Patient needed a cane and a scooter for ambulation; died in his early 30s (death possibly unrelated to EDMD)
▼ Recurrent mutations									
6537 [†]	p.N39S	M	<20 months	Died at age 13	Sporadic*	Limb-girdle, proximal upper and distal lower weakness	Ankle (<age 4), knee (age 7), neck and elbow (age 9)	Right bundle branch block, AV block, atrial flutter, atrial fibrillation age 7, pacemaker at age 13	In wheelchair at age 4; patient died at age 13 of cardiac failure
5182	p.Y45C	M	n.a.	15	Sporadic	n.a.	n.a.	Severe dilated cardiomyopathy associated with muscular dystrophy, atrial flutter/fibrillation	n.a.
563	p.T150P	F	n.a.	38	Familial	Progressive limb weakness	Neck and elbow	Cardiac arrhythmia at age 22	n.a.
7897	p.R249W	M	n.a.	6	Familial?	Wasting of humeral muscles	Neck	n.a.	n.a.
61 [†]	p.R249W	M	1	10	n.a.	Wasting/weakness of biceps, triceps, brachii	Elbow and ankle	n.a.	Initially diagnosed with FSHD; asymptomatic mother, grandfather with cardiac abnormalities
8281 [†]	p.R249W	F	<1	13	Sporadic	Limb-girdle, proximal upper and distal lower weakness	Ankle (<age 3), elbow (age 6) and neck (age 11)	Primary AV block, prolonged PR-interval (age 6), prolapse of mitral valve with mitral insufficiency	Initially diagnosed with Spinal muscular atrophy
3 [#]	p.R249W; p.R644C	F	<2	12	Sporadic	n.a.	Elbow and knee (age 5)	Mild ventricular enlargement with normal function at age 10, no cardiac disease or atrial arrhythmias at age 18	Non-ambulatory at age 5
9696	p.R249Q	F	n.a.	26	Sporadic	Proximal and distal upper and lower extremity weakness	Neck, elbows and knees	n.a.	n.a.

167 [¶]	p.R249Q	F	<2	28	Familial	CMD phenotype; distal and upper lower extremity weakness, facial weakness	Elbow	n.a.	Congenital cataracts, nystagmus, glaucoma
1943	p.L271P	M	n.a.	12	Familial	Humeroperoneal weakness	Elbow and tibialis anterior	Cardiomyopathy	n.a.
2111	p.Q294P	F	n.a.	33	Familial	EDMD phenotype	n.a.	n.a.	n.a.
149 [¶]	p.S303P	M	<2	16	Sporadic	Mild proximal upper and lower weakness	n.a.	Normal sinus rhythm borderline prolonged PR-interval with occasional premature supraventricular complexes, poor R-wave progression	n.a.
2570 [¶]	p.E358K	M	n.a.	13	Sporadic	Proximal upper, distal lower and limb-girdle weakness;	Neck, elbow, ankle and knee	Dysrhythmia with prolonged PR-interval (age 13)	Wheelchair at age 5
8419 [¶]	p.E358K	F	n.a.	7	Familial	Severe EDMD phenotype	n.a.	n.a.	n.a.
26 [¶]	p.E358K	M	2	7	Sporadic	Proximal and distal lower extremity weakness	Elbow, ankle, knee and hip	n.a.	n.a.
2631	p.R386K	M	n.a.	30	Sporadic	n.a.	n.a.	n.a.	n.a.
5653	p.R386K	F	n.a.	33	n.a.	EDMD phenotype	n.a.	n.a.	n.a.
7309	p.R453W	M	n.a.	24	Familial	Mild proximal weakness;	Neck and heel cord	Echocardiogram shows mildly enlarged left atrium and ventricle, mild global hypokinesis and reduced systolic function, estimated LVEF 45%	CK level 2607U/L
565	p.R453W	M	n.a.	36	n.a.	EDMD phenotype	n.a.	First degree heart block	n.a.
2975	p.R453W	M	n.a.	32	Sporadic	Limb-girdle, proximal upper, distal lower	Neck, elbow, ankle and knee	Beta blockers at age 22, pacemaker at age 32	Wheelchair at age 14
5176	p.R453W	M	<4	19	Sporadic	Limb-girdle, proximal upper, distal lower	Neck, elbow and ankle	No cardiac involvement	n.a.
1283	p.R453W	F	6	28	Familial	Leg weakness (foot-drop like gait)	Elbow	EMG-diffuse myopathic process; cardiac involvement	Spinal fusion for sever thoracic-lumbar scoliosis (age 20); normal muscle biopsy (age 22) and normal CK level
68	p.R453W	M	3	7	Sporadic	LGMD phenotype; proximal lower extremity weakness	Hip	Normal electrocardiography	Increased CK level (2012U/L); muscle biopsy showed scattered hyper-contracted fibers often associated with a membrane protein defect
1412	c.IVS7-2A>G (c.1381-2A>G)	M	n.a.	17	Sporadic	EDMD phenotype; muscular atrophy	Neck extensor, elbow flexor and ankle (severe), knee (minimal)	n.a.	Scoliosis requiring surgery
6388 [#]	c.IVS7-1G>T (c.1381-1G>T); p.D461Y	F	<1	6	Familial	Proximal upper and limb-girdle weakness	Neck, elbow, ankle and knee	Cardiac catheterization (age 3); suggestive of probably early cardiomyopathy	n.a.
2974	p.T510YfsX42	M	n.a.	51	Sporadic	Mild proximal upper weakness at age 50	Mild elbow contractures	Arrhythmia onset in 20s, pacemaker placement recommended at age 29, placed at age 42 when patient experienced incomplete heart block, heart transplant at age 51	n.a.
7288 [¶]	p.R527P	M	<3	5	Familial	Proximal upper and limb-girdle weakness	None	Right bundle branch block diagnosed <age 4	n.a.
1527	p.T528K	M	n.a.	11	Sporadic	n.a.	n.a.	n.a.	n.a.
1200	p.T528R	M	n.a.	12	n.a.	n.a.	n.a.	n.a.	n.a.
2257 [¶]	p.T528R	F	1	12	Sporadic	Congenital myopathy phenotype; distal lower weakness	Bilateral elbow contractures (age 11), neck, ankle	Normal EMG, myopathic biopsy, no cardiac issues at age 11	Progressive arthrogryposis , increased CK level
2743	p.R541S	M	n.a.	13	Familial	n.a.	n.a.	Dilated cardiomyopathy; congestive heart failure requiring transplant	Family history of various degrees of DCM and LGMD1B, loss of adipose tissue in females
198	p.R541P	F	Childhood	52	Familial	LGMD1B phenotype; proximal upper, limb-girdle, distal lower weakness, loss of muscle mass (age 19)	Elbow, knee	Atrial fibrillation	One child with EDMD, other with LGMD1B
853	p.G602S	M	n.a.	6	Sporadic	Limb-girdle weakness (age 11)	Hamstrings, elbows, neck and rigid spine	Cardiac defect (atrial septal defect)	n.a.
51 [¶]	p.R644C	M	Birth	19	Sporadic	Weakness and hypotonia of the proximal musculature of the upper and lower extremities and broad based gait (age 3)	Elbow and ankle	n.a.	Progression until age 10, then stabilization; CK level 1400U/L

[¶] Patients with a severe phenotype and single *LMNA* mutation

[#] Compound heterozygous patients with a severe phenotype

* Patients confirmed to be sporadic cases of EDMD by molecular analysis of family members including parents and siblings

Abbreviations: n.a., data not available; AV, Atrioventricular; CK, Creatine kinase; EMG, Electromyography; LVEF, Left ventricular ejection fraction

Table 3. Summary of *LMNA* mutations and encoded protein

ID#	<i>LMNA</i> mutation	<i>LMNA</i> exon/ intron	Predicted amino acid change	Mutation type	Protein domain affected	Ref. for published mutations
▼ Novel mutations						
91	c.357C>T	2	p.R119R	Silent	Coil 1b	Novel
3734	c.566_567delinsCC	3	p.R189P	Missense	Coil 1b	Novel
2952	c.568_570dup	3	p.R190dup	Duplication (In frame insertion)	Coil 1b	Novel
8542	c.618C>G	3	p.F206L	Missense	Coil 1b	Novel
8434	c.802T>C	4	p.S268P	Missense	Coil 2b	Novel
2018	c.810G>A	4	p.K270K	Silent	Coil 2b	Novel
778	c.810G>A	4	p.K270K	Silent	Coil 2b	Novel
33	c.IVS4+1G>A (c.810+1G>A)	IVS 4		Splice site		Novel
6298	c.883T>C	5	p.S295P	Missense	Coil 2b	Novel
116	c.1064_1066del	6	p.Q355del	In frame deletion	Coil 2b	Novel
2785	c.1081G>A	6	p.E361K	Missense	Coil 2b	Novel
7975	c.IVS6-2A>G (c.1159-2A>G)	IVS 6		Splice site		Novel
342	c.1346G>A	7	p.G449D	Missense	Tail (Ig-fold)	Novel
9106	c.1361T>C	7	p.L454P	Missense	Tail (Ig-fold)	Novel
7461	c.1399T>C	8	p.W467R	Missense	Tail (Ig-fold)	Novel
2660	c.IVS8+1G>A (c.1488+1G>A)	IVS 8		Splice site		Novel
▼ Recurrent mutations						
6537	c.116A>G	1	p.N39S	Missense	Coil 1a	(Benedetti, et al., 2007; Quijano-Roy, et al., 2008)
5182	c.134A>G	1	p.Y45C	Missense	Coil 1a	(Bonne, et al., 2000)
563	c.448A>C	2	p.T150P	Missense	Coil 1b	(Felice, et al., 2000)
7897	c.745C>T	4	p.R249W	Missense	Coil 2a	(Quijano-Roy, et al., 2008)
61	c.745C>T	4	p.R249W	Missense	Coil 2a	same as above
8281	c.745C>T	4	p.R249W	Missense	Coil 2a	same as above
3	c.745C>T; c.1930C>T	4; 11	p.R249W; p.R644C	Missense	Coil 2a; Tail (Lamin A specific)	(Quijano-Roy, et al., 2008); (Csoka, et al., 2004; Genschel, et al., 2001; Mercuri, et al., 2005; Muntoni, et al., 2006; Pasotti, et al., 2008; Perrot, et al., 2009; Rankin, et al., 2008)
9696	c.746G>A	4	p.R249Q	Missense	Coil 2a	(Benedetti, et al., 2007; Bonne, et al., 2000; Boriani, et al., 2003; Brown, et al., 2001; Ki, et al., 2002; Muchir, et al., 2004; Raffaele Di Barletta, et al., 2000; Rudenskaya, et al., 2008; Vytopil, et al., 2003)
167	c.746G>A	4	p.R249Q	Missense	Coil 2a	same as above
1943	c.812T>C	5	p.L271P	Missense	Coil 2b	(Kichuk Chrisant, et al., 2004)
2111	c.881A>C	5	p.Q294P	Missense	Coil 2b	(Bonne, et al., 2000)
149	c.907T>C	5	p.S303P	Missense	Coil 2b	(Onishi, et al., 2002)
2570	c.1072G>A	6	p.E358K	Missense	Coil 2b	(Benedetti, et al., 2007; Bonne, et al., 2000; Brown, et al., 2001; Mercuri, et al., 2004; Quijano-Roy, et al., 2008)
8419	c.1072G>A	6	p.E358K	Missense	Coil 2b	same as above
26	c.1072G>A	6	p.E358K	Missense	Coil 2b	same as above
2631	c.1157G>A	6	p.R386K	Missense	Coil 2b	(Bonne, et al., 2000; Boriani, et al., 2003)
5653	c.1157G>A	6	p.R386K	Missense	Coil 2b	same as above
7309	c.1357C>T	7	p.R453W	Missense	Tail (Ig-fold)	(Benedetti, et al., 2007; Bonne, et al., 1999; Bonne, et al., 2000; Brette, et al., 2004; Colomer, et al., 2002; Fidzianska and Glinka, 2006; Golzio, et al., 2007; Muchir, et al., 2004; Raffaele Di Barletta, et al., 2000; Vytopil, et al., 2003)
565	c.1357C>T	7	p.R453W	Missense	Tail (Ig-fold)	same as above
2975	c.1357C>T	7	p.R453W	Missense	Tail (Ig-fold)	same as above
5176	c.1357C>T	7	p.R453W	Missense	Tail (Ig-fold)	same as above
1283	c.1357C>T	7	p.R453W	Missense	Tail (Ig-fold)	same as above
68	c.1357C>T	7	p.R453W	Missense	Tail (Ig-fold)	same as above
1412	c.IVS7-2A>G (c.1381-2A>G)	IVS 7		Splice site		(Quijano-Roy, et al., 2008)
6388	c.IVS7-1G>T (c.1381-1G>T); c.1381G>T	IVS 7/ exon 8	p.D461Y	Splice site; Missense	Tail (Ig-fold)	(Bakay, et al., 2006)
2974	c.1526dup	9	p.T510YfsX42	Frame shift	Tail (Ig-fold)	(Arbustini, et al., 2005)
7288	c.1580G>C	9	p.R527P	Missense	Tail (Ig-fold)	(Benedetti, et al., 2007; Bonne, et al., 1999; Bonne, et al., 2000; Brown, et al., 2001; Raffaele Di Barletta, et al., 2000; van der Kooi, et al., 2002)
1527	c.1583C>A	9	p.T528K	Missense	Tail (Ig-fold)	(Benedetti, et al., 2007; Bonne, et al., 2000; Fokkema, et al., 2005; Raffaele Di Barletta, et al., 2000)
1200	c.1583C>G	9	p.T528R	Missense	Tail (Ig-fold)	(Fokkema, et al., 2005; Vytopil, et al., 2003)
2257	c.1583C>G	9	p.T528R	Missense	Tail (Ig-fold)	same as above
2743	c.1621C>A	10	p.R541S	Missense	Tail	(Sylvius, et al., 2005)
198	c.1622G>C	10	p.R541P	Missense	Tail	(van Tintelen, et al., 2007)
853	c.1804G>A	11	p.G602S	Missense	Tail (Lamin A specific)	(Bakay, et al., 2006; Young, et al., 2005)
51	c.1930C>T	11	p.R644C	Missense	Tail (Lamin A specific)	(Csoka, et al., 2004; Genschel, et al., 2001; Mercuri, et al., 2005; Muntoni, et al., 2006; Pasotti, et al., 2008; Perrot, et al., 2009; Rankin, et al., 2008)

LMNA GenBank Accession Number RefSeq NM_170707.2; Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.

Figure 1

200x210mm (300 x 300 DPI)

Figure 2

174x214mm (300 x 300 DPI)

Figure 3

181x214mm (300 x 300 DPI)

Figure 4

206x218mm (300 x 300 DPI)

Figure 4

206x218mm (300 x 300 DPI)